Étude close S-AVANT – C13-1

Titre de l’étude

Follow-up to the AVANT study up to 8 and 10 years (median follow up) in patients with colon carcinoma

Promoteur

GERCOR 151 rue du Faubourg St Antoine 75011 PARIS – France

Investigateur Coordonateur

Service :
–
Email:

ARC Coordonnateur

NellyROLDAN
Email: nelly.roldan@gercor.com.fr

Objectif principal

Overall Survival (OS) of the stage III population randomized in the AVANT study

Objectifs secondaires

  • OS in stage III alive patients not lost to follow up at 8 years median follow up
  • OS in stage II patients
  • OS and DFS in elderly patients
  • OS after relapse and management of relapse
  • Disease-Free Survival
  • Relapse-Free Survival
  • Cancer Specific Survival
  • Time to Relapse
  • Second cancer rate
  • Co-morbidities
  • Prognostic factors

Nombre de patients

Un total de3000 patients est à inclure pour l’analyse finale.

Population de l’étude

Principaux critères d’inclusion

  1. All patients randomized in the AVANT trial (3451 patients).

Principaux critères de non inclusion

  1. Patients opposed to the collection of their medical data (The use of a new ICF will depend on local regulatory requirements).